白藜蘆醇 Resveratrol × 第二型糖尿病
The totality of evidence for resveratrol in type 2 diabetes is genuinely conflicted and does not support a confident positive grade.
The totality of evidence for resveratrol in type 2 diabetes is genuinely conflicted and does not support a confident positive grade. The two highest-quality syntheses point AGAINST a meaningful benefit: the Cochrane review (PMID 31978258) found null effects on HbA1c, fasting glucose and HOMA-IR, and the high-quality umbrella review (PMID 34320173) explicitly concludes current evidence does NOT support resveratrol for cardiometabolic management in T2D; the largest single RCT (PMID 27520400, n=192, 6 months) was also null at both 40 mg and 500 mg/day. Conversely, several moderate-quality meta-analyses report statistically significant reductions in HbA1c, HOMA-IR and fasting glucose, but these effects are small, heterogeneous, and concentrated in high-dose (>=1000 mg/day) subgroups and short trials (<12 weeks) that few real-world products or users achieve. Examine grades the glycemic outcomes B (Small Improvement), but this conflicts with the Cochrane/umbrella conclusions and the ADA position, so I weight it down. Given the unresolved conflict, the dependence of any benefit on doses well above the EU/Taiwan regulatory cap of 150 mg/day, and the absence of any society endorsement, the honest grade is C: evidence exists but is small, inconsistent and uncertain.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.41
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣社群幾乎沒有『鄉民自己拿白藜蘆醇控血糖』的真實實測心得；PTT 糖尿病/血糖討論串（regimen、WomenTalk、Health）多談飲食、運動、減重與藥物，極少提及白藜蘆醇。與糖尿病連結的內容主要來自婕斯（沛泉菁華）、美安等直銷話術——宣稱『吃藥傷身、吃白藜蘆醇調整身體就能控糖、不用一輩子吃藥』，被美的好朋友與營養師（呂孟凡、formulawave）反覆打臉：人體試驗結果不一致，2013 美國糖尿病學會期刊研究顯示對血糖、血壓、內臟脂肪、發炎指標皆無影響。整體訊號被業配主導，缺乏可信的在地實測經驗。
無共識（缺乏真實在地實測心得；社群少有人專為控血糖服用，僅見直銷誇大宣稱，醫療端則持否定態度）
- 醫療衛教提及高劑量可能腹瀉、胃痛、噁心、食欲不振（非糖尿病情境的一般反饋）
- 社群未見糖尿病使用者回報具體副作用（因專為控糖服用者極少）
依論壇被提及頻率，非銷售或品質排序。
- 婕斯 Jeunesse 沛泉菁華（Reserve，直銷，常見糖尿病療效話術來源）
- 美安 Market America（直銷，常與白藜蘆醇/OPC-3 併同討論）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 醫療營養治療與減重
- 規律身體活動
- Metformin（二甲雙胍）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-type2-diabetes-INT-resveratrol-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "白藜蘆醇能改善第二型糖尿病",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}